- 4-Week # shares sold: 5,000
- 12-Week # shares sold: 14,671
- 24-Week # shares bought: 700,000
- 24-Week # shares sold: 30,671
In highlights from this week's trading diary and posts, Kass tells us about underlying risks in speculative biotechs and how Donald Trump's voice makes bonds slide.
Citi lowered Portola Pharmaceuticals' (PTLA) stock rating to 'neutal' this morning.
The FDA asked Portola Pharmaceuticals (PTLA) to provide more information on a new anticoagulation reversal drug.